| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 24,500 | 25,950 | 08:38 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | BASTIDE: Organic growth of 8.2% in first-half 2025-2026: Confirmed excellent growth momentum in home healthcare services: 9.2% / Accelerated growth in the Homecare business, up 6.5% // 2025-2026 targets confirmed | 286 | Actusnews Wire | Caissargues, February 12, 2026 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-half 2025-2026, ending December 31, 2025.
In... ► Artikel lesen | |
| BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | BASTIDE: Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in home healthcare services, up 10.7% / Homecare business up 4.7%, driven by the healthcare institutions business (up 8.5%) | 438 | Actusnews Wire | Caissargues, November 13, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2025-2026, ending September 30, 2025.
In... ► Artikel lesen | |
| 28.10.25 | BASTIDE: 2025-2026 financial calendar | 977 | Actusnews Wire | Caissargues, October 28, 2025
Events
Dates*
2025-2026 Q1 Revenue
Thursday November 13, 2025
2025-2026 H1 Revenue
Thursday February 12, 2026
2025-2026 H1 Results
Wednesday... ► Artikel lesen | |
| 22.10.25 | BASTIDE: 2024-2025 annual results in line with targets // 2025-26 outlook: Revenue of over EUR 510 million and recurring operating margin around 9%, Leverage of less than 3x and decrease in financial expenses | 773 | Actusnews Wire | Caissargues, October 22, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has announced its 2024-2025 annual results at June 30, 2025. The 2024-2025 annual consolidated... ► Artikel lesen | |
| 24.09.25 | BASTIDE: Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group | 721 | Actusnews Wire | Caissargues, September 24, 2025
In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory... ► Artikel lesen | |
| 04.09.25 | BASTIDE: 2024-2025 revenue target met // 2024-2025 revenue from continuing operations: EUR 491 million, up 8% ( EUR 561 million, excluding impact of disposals) | 530 | Actusnews Wire | Caissargues, September 4, 2025
Groupe Bastide has published its annual revenue for 2024-2025. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no... ► Artikel lesen | |
| 30.06.25 | BASTIDE: Bastide Groupe Sells Baywater Healthcare To Sapio Group | 686 | Actusnews Wire | Crewe, United Kingdom & Monza, Italy - 30th June 2025
Bastide le Confort Medical SA (hereinafter "Groupe Bastide") today announced that it has agreed to the sale of its subsidiary Baywater Healthcare... ► Artikel lesen | |
| 09.06.25 | BASTIDE: Disposal of CICADUM and MEDSOFT | 569 | Actusnews Wire | Caissargues, June 9, 2025
Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned... ► Artikel lesen | |
| 05.06.25 | BASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium | 549 | Actusnews Wire | Caissargues, June 5, 2025
Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for... ► Artikel lesen | |
| 04.06.25 | BASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK | 502 | Actusnews Wire | Caissargues, June 4, 2025
After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region... ► Artikel lesen | |
| 15.05.25 | BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed | 501 | Actusnews Wire | Caissargues, May 15, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
| 19.03.25 | BASTIDE: 2024-2025 half-year results / Recurring operating margin at 9.1%, up 80 bps / Operating FCF positive at EUR 9.4 million / Improvement in financial leverage / upward revision of recurring operating margin target to 9.1% | 647 | Actusnews Wire | Caissargues, March 19, 2025 - Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ANSELL | 19,300 | +0,52 % | ANSELL LIMITED: Notification of cessation of securities - ANN | ||
| AMBEA | 12,110 | +0,50 % | Ambea AB: Ambea Year-end Report January-December 2025 | Significant investments in future growth
CEO's statement:
In the last quarter of the year, we continued investing strongly in growth through acquisitions and new operations as well as through developing... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,370 | 0,00 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| FRESENIUS | 50,78 | 0,00 % | Märkte am Morgen: Warner Bros-Übernahme, PayPal, AMC Entertainment, Fresenius, Jost Werke | Der DAX ist nach dem schwachen Handel am Montag auch gestern nicht in die Gänge gekommen. Letzten Endes ging der DAX 0,02 Prozent tiefer bei 24.986 Punkten aus dem Handel. Heute könnte er die Rückkehr... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,840 | 0,00 % | DAX-Check LIVE: Aixtron, CEWE, Elmos, FMC, MTU, SFC Energy im Fokus | Neue Zolldrohungen aus Washington haben den deutschen Aktienmarkt zum Wochenstart unter Druck gesetzt. Der DAX fiel 1,06 Prozent auf 24.991 Punkte und rutschte damit wieder unter die Marke von 25.000... ► Artikel lesen | |
| GENEDX | 74,20 | -6,98 % | These Analysts Slash Their Forecasts On GeneDx After Q4 Results | ||
| PROGYNY | 17,600 | 0,00 % | KeyBanc senkt Kursziel für Progyny-Aktie aufgrund konservativer Schätzungen | ||
| PROCEPT BIOROBOTICS | 25,920 | 0,00 % | PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance | SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 41,570 | +0,46 % | BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance | LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 25,800 | 0,00 % | Carl Zeiss Meditec AG: ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options | Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate - whether as a standalone cloud application or as an integrated... ► Artikel lesen | |
| GERRESHEIMER | 16,120 | 0,00 % | Gerresheimer AG: Vertrauenskrise eskaliert; BaFin erweitert die Untersuchung. Einstufung auf VERKAUFEN. | Gerresheimer (GXI) hat in einer ad-hoc Mitteilung bekannt gegeben, dass die BaFin ihre Prüfung für das Geschäftsjahr 2024 ausgeweitet und eine Sonderprüfung weiterer Berichte eingeleitet hat. Dies geschieht... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,640 | +2,19 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen | |
| HEARTFLOW | 24,050 | +4,00 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| ECKERT & ZIEGLER | 15,110 | 0,00 % | EQS-AFR: Eckert & Ziegler SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Eckert & Ziegler SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Eckert & Ziegler SE: Vorabbekanntmachung... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,020 | +1,22 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results | All 2025 Operating and Financial Metrics At or Above High End of Guidance RangesFull-year 2025 Net Income +59.3% from 2024Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024Full-year... ► Artikel lesen |